Fractional vs. FSP vs. CRO: choosing the right model for your trial

Every sponsor faces the same question when planning a clinical trial: who is going to do the work? You can build an internal team, outsource everything, or land somewhere in between. The three most common models are fractional resourcing, FSP (Functional Service Provider), and full-service CRO (Contract Research Organization).

Each model works well in the right context and fails badly in the wrong one. Here’s how to choose.

The three models

Fractional

A fractional model means bringing in experienced clinical operations professionals on a part-time or project basis. They work embedded with your team, attend your meetings, use your systems, and contribute both strategic thinking and hands-on execution. But they’re not full-time employees.

Think of it as renting senior expertise by the hour or by the project.

Best for:

• Early-stage biotechs that need experienced leadership but can’t justify a full-time VP of Clinical Operations
• Specific project needs: writing a monitoring plan, setting up a TMF (Trial Master File), designing a site selection strategy
• Gap coverage when a key team member leaves and you need someone experienced immediately
• Companies running one or two trials that don’t need a permanent infrastructure

Strengths:

• Access to senior talent that would be hard to recruit full-time at a small company
• Flexibility to scale up or down based on trial phase and workload
• Direct integration with your team, so knowledge stays in-house
• Lower commitment than a full-time hire or a large outsourcing contract

Watch out for:

• Availability. Fractional resources work with multiple clients. If your trial hits a crisis, you’re sharing their calendar.
• Continuity. If the engagement is short-term, you need a plan for knowledge transfer when it ends.
• Scope creep. A fractional engagement works best with clearly defined deliverables. Without them, the work expands without structure.

FSP (Functional Service Provider)

An FSP model means outsourcing specific clinical trial functions to an external provider while keeping strategic oversight and decision-making in-house. You might outsource monitoring, data management, biostatistics, or regulatory submissions, but your internal team manages the trial overall.

The FSP staff often work as an extension of your team, using your SOPs (Standard Operating Procedures), your systems, and your processes. The difference from a CRO is that you retain control of the trial strategy and cross-functional coordination.

Best for:

• Sponsors with internal clinical operations capability who need additional hands for specific functions
• Companies that want to maintain strategic control but lack capacity in one or two areas
• Trials where specific expertise is needed (biostatistics, pharmacovigilance) that the internal team doesn’t have
• Organizations that have been burned by full-service CRO relationships and want more visibility

Strengths:

• You keep control of the trial. Decisions about enrollment strategy, protocol amendments, and site management stay with your team.
• FSP resources work within your processes, so there’s less friction than managing a CRO’s separate systems and SOPs.
• You can mix and match. Outsource monitoring but keep data management in-house. Or the reverse.
• More cost transparency than a full-service model, because you’re paying for defined functions, not a bundled package.

Watch out for:

• You need internal infrastructure. FSP only works if you have someone internally who can manage the outsourced functions and integrate them with the rest of the trial.
• Quality depends on your oversight. A CRO is contractually accountable for its scope of work, but under ICH E6 the sponsor retains oversight responsibility and owns the regulatory outcome in every model. In FSP that oversight is more hands-on: you are the one checking that the outsourced team performs to standard, day to day.
• Onboarding takes time. FSP resources need to learn your systems, your processes, and your therapeutic area. Factor in a ramp-up period.

Full-service CRO

A CRO takes on the operational execution of your clinical trial from start to finish. They manage site selection, regulatory submissions, monitoring, data management, safety reporting, and study close-out. The sponsor provides strategic direction and medical oversight, but the CRO runs the operation.

Best for:

• Large, complex, multi-country trials where the operational scale exceeds what an internal team can manage
• Sponsors with minimal or no internal clinical operations infrastructure
• Programs that need to move fast and can’t afford the time to build an internal team
• Therapeutic areas where specialized CRO expertise provides a real advantage (oncology, rare disease, medical devices)

Strengths:

• Scale. A large CRO can deploy dozens of CRAs, open sites in 30 countries, and handle regulatory requirements across all of them.
• Established processes. SOPs, training programs, quality systems, and technology platforms are already in place.
• Speed to start. You don’t need to hire, train, or build infrastructure. The CRO has it.
• Contractual accountability. The CRO is contractually responsible for delivering its scope of work. Keep in mind that this does not transfer regulatory responsibility: under ICH E6, the sponsor still owns oversight of the trial and answers for the outcome with regulators.

Watch out for:

• Loss of visibility. Once you hand off operations, it’s harder to know what’s actually happening at the site level. You’re relying on the CRO’s reporting, which may not match what you’d prioritize.
• Staff turnover. CROs move people across accounts. The CRA who started your trial may not be the one who finishes it. Your sites notice.
• Change orders. The initial contract covers a defined scope. Anything outside it, extra monitoring visits, additional sites, protocol amendments, results in change orders that add up fast.
• Misaligned incentives. The CRO is paid for activity (site visits, document processing, data queries). You’re paying for outcomes (clean data, enrolled patients, study completion). Those aren’t always the same thing.

How to choose

The decision comes down to three factors:

1. What internal capability do you have?

If you have an experienced clinical operations team, FSP or fractional resources fill gaps without giving up control. If you have a small team or no team, a CRO provides the infrastructure you don’t have.

2. How much control do you need?

Sponsors in early-stage programs often need tight control because every decision affects the next funding round. A CRO model works better when the program is well-defined and you need execution at scale.

3. What’s the trial complexity?

A single-site Phase I study doesn’t need a global CRO. A 200-site Phase III trial probably does. Match the model to the scale and complexity of the work.

Combining models

Most sponsors end up with a hybrid approach. A CRO handles monitoring and data management. A fractional regulatory expert manages submissions. An FSP provides biostatistics support. The internal team coordinates everything.

This works, but only if you define boundaries clearly. The most common failure in hybrid models is ambiguity about who owns what. Write it down. Make it specific. Review it when the team or scope changes.

Where to start

Before your next trial, map out every function that needs to be performed: monitoring, data management, regulatory, safety, medical writing, biostatistics, project management. For each function, decide: build internally, outsource via FSP, outsource via CRO, or engage a fractional expert.

Make the decision based on your team’s actual capacity, not what you hope to hire in six months. Then write down, for each function, who at your company is responsible for overseeing it. If that column has blanks, you have found the gaps before an inspector does, and you can fill them with a fractional lead, an FSP arrangement, or a hire, whichever fits.